Enanta Pharmaceuticals In...

NASDAQ: ENTA · Real-Time Price · USD
7.67
-0.07 (-0.90%)
At close: Aug 15, 2025, 12:52 PM

Enanta Pharmaceuticals Income Statement

Financials in USD. Fiscal year is October - September.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Sep 30, 2024 Sep 30, 2023 Sep 30, 2022 Sep 30, 2021
Revenue
67.64M 79.2M 86.16M 97.07M
Cost of Revenue
n/a 2.37M 2.97M n/a
Gross Profit
67.64M 79.2M 86.16M 97.07M
Operating Income
-121.69M -137.21M -123.84M -109.57M
Interest Income
14.77M 11.36M 1.57M 2.02M
Pretax Income
-117.79M -131M -122.19M -107.58M
Net Income
-116.05M -133.82M -121.75M -79M
Selling & General & Admin
57.85M 52.89M 45.48M 32.54M
Research & Development
131.48M 163.52M 164.52M 174.11M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
189.33M 216.41M 210M 206.65M
Interest Expense
10.94M 5.15M n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
189.33M 216.41M 210M 206.65M
Income Tax Expense
-1.74M 2.82M -433K -28.58M
Shares Outstanding (Basic)
21.16M 20.97M 20.6M 20.17M
Shares Outstanding (Diluted)
21.16M 20.97M 20.6M 20.17M
EPS (Basic)
-5.48 -6.38 -5.91 -3.92
EPS (Diluted)
-5.48 -6.38 -5.91 -3.92
EBITDA
-104.51M -123.48M -119.22M -104.25M
EBIT
-106.85M -125.85M -122.19M -107.58M
Depreciation & Amortization
2.34M 2.37M 2.97M 3.33M